NCT05129891View on ClinicalTrials.gov

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

February 26, 2023

Study Completion Date

May 4, 2023

Conditions
Healthy VolunteersHigh Blood Cholesterol LevelsType 2 Diabetes
Interventions
DRUG

Semaglutide D

Tablet given orally

DRUG

Semaglutide G

Tablet given orally

DRUG

Semaglutide H

Tablet given orally

DRUG

Semaglutide I

Tablet given orally

DRUG

NNC0385-0434 B

Tablet given orally

DRUG

NNC0385-0434 C

Tablet given orally

DRUG

NNC0385-0434 D

Tablet given orally

DRUG

NNC0385-0434 E

Tablet given orally

Trial Locations (2)

14050

Parexel International GmbH, Berlin

H3P 3P1

Altasciences Company Inc., Montreal

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY